Edition:
United States

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

6.03USD
23 May 2018
Change (% chg)

$0.03 (+0.42%)
Prev Close
$6.00
Open
$6.20
Day's High
$6.20
Day's Low
$5.95
Volume
20,941
Avg. Vol
12,389
52-wk High
$13.30
52-wk Low
$4.10

Chart for

About

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $70.92
Shares Outstanding(Mil.): 10.79
Dividend: --
Yield (%): --

Financials

  TRIL.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -5.03 -- --
ROI: -52.37 1.57 14.38
ROE: -126.37 2.43 16.07

BRIEF-Trillium Therapeutics Files Prospectus Related To Offering Of 2.35 Mln Co's Common Shares By Selling Shareholders

* TRILLIUM THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFERING OF 2.35 MILLION CO'S COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2IoCJmp) Further company coverage:

May 16 2018

BRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs

* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS

Apr 10 2018

BRIEF-Trillium Therapeutics' TTI-621 Receives Orphan Drug Designation For Treatment Of Cutaneous T-Cell Lymphoma

* TRILLIUM THERAPEUTICS' TTI-621 RECEIVES ORPHAN DRUG DESIGNATION FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

Mar 20 2018

BRIEF-Trillium Therapeutics Reports Annual 2017 Financial And Operating Results

* TRILLIUM THERAPEUTICS REPORTS ANNUAL 2017 FINANCIAL AND OPERATING RESULTS

Mar 09 2018

BRIEF-Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln

* TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text : http://bit.ly/2jZxGi0 Further company coverage:

Dec 15 2017

BRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics

* MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2yOHuTW) Further company coverage:

Dec 08 2017

Earnings vs. Estimates